Susquehanna International Group
RLMD icon

Susquehanna International Group’s Relmada Therapeutics RLMD Stock Holding History

Susquehanna International Group’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.96M Buy
281,800
+234,600
+497% +$1.11M ﹤0.01% 6226
2025
Q4 		$228K Sell
47,200
-18,800
-28% -$63K ﹤0.01% 10580
2025
Q3 		$133K Buy
+66,000
New +$63.3K ﹤0.01% 11379
2025
Q1 		– Sell
-209,900
Closed -$109K – 13300
2024
Q4 		$109K Buy
209,900
+82,600
+65% +$201K ﹤0.01% 11270
2024
Q3 		$412K Buy
127,300
+97,000
+320% +$314K ﹤0.01% 8932
2024
Q2 		$90.9K Buy
30,300
+6,500
+27% +$23.5K ﹤0.01% 11088
2024
Q1 		$111K Buy
+23,800
New +$115K ﹤0.01% 11152
2023
Q1 		– Sell
-145,400
Closed -$507K – 13347
2022
Q4 		$507K Sell
145,400
-71,500
-33% -$628K ﹤0.01% 7827
2022
Q3 		$8.03M Buy
216,900
+73,900
+52% +$2.05M ﹤0.01% 2465
2022
Q2 		$2.72M Buy
143,000
+23,300
+19% +$508K ﹤0.01% 4256
2022
Q1 		$3.23M Buy
119,700
+49,400
+70% +$1.02M ﹤0.01% 4485
2021
Q4 		$1.58M Buy
70,300
+9,700
+16% +$216K ﹤0.01% 6081
2021
Q3 		$1.59M Buy
60,600
+3,500
+6% +$93.7K ﹤0.01% 6341
2021
Q2 		$1.83M Sell
57,100
-22,800
-29% -$792K ﹤0.01% 6122
2021
Q1 		$2.81M Buy
79,900
+36,400
+84% +$1.27M ﹤0.01% 5109
2020
Q4 		$1.4M Sell
43,500
-22,100
-34% -$759K ﹤0.01% 5907
2020
Q3 		$2.47M Sell
65,600
-6,800
-9% -$263K ﹤0.01% 4223
2020
Q2 		$3.24M Buy
72,400
+47,400
+190% +$2M ﹤0.01% 3670
2020
Q1 		$853K Sell
25,000
-2,800
-10% -$113K ﹤0.01% 5754
2019
Q4 		$1.08M Buy
+27,800
New +$845K ﹤0.01% 5375

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Susquehanna International Group's RLMD Position: Q1 2026 in Review

Susquehanna International Group increased its Relmada Therapeutics (RLMD) stake by 162% in Q1 2026, buying an estimated $2.96M and bringing the position to 1,011,572 shares worth $7.04M. The position accounts for ﹤0.01% of the portfolio, ranked #3650.

Susquehanna International Group first reported a position in RLMD in Q4 2019 and has held it in 20 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Susquehanna International Group held 1,011,572 shares of Relmada Therapeutics worth $7.04M as of Q1 2026.
  • Susquehanna International Group bought 625,630 Relmada Therapeutics shares in Q1 2026, an estimated $2.96M.
  • Relmada Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #3650 holding.
  • Susquehanna International Group first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 20 quarters since.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.